MX2014015557A - Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada. - Google Patents

Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.

Info

Publication number
MX2014015557A
MX2014015557A MX2014015557A MX2014015557A MX2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A MX 2014015557 A MX2014015557 A MX 2014015557A
Authority
MX
Mexico
Prior art keywords
receptor ligand
conjugates
altered
region
effector function
Prior art date
Application number
MX2014015557A
Other languages
English (en)
Inventor
Matthias Rueth
Richard D Dimarchi
Erhard Kopetzki
Georg Tiefenthaler
Eike Hoffmann
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of MX2014015557A publication Critical patent/MX2014015557A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se reporta en la presente un polipéptido de fusión de región Fc o conjugado de región Fc que comprende uno a cuatro polipéptidos de ligando receptor de incretina y una región Fc humana variante con una mutación del residuo de aminoácido en la posición 329 y por lo menos una mutación adicional de por lo menos un aminoácido seleccionado del grupo que comprende residuos de aminoácido en las posiciones 228, 233, 234, 235, 236, 237, 297, 318, 320, 322 y 331 a un residuo diferente, en donde los residuos en la región Fc se numeran de acuerdo con el índice EU de Kabat y su uso como un medicamento.
MX2014015557A 2012-06-21 2013-06-18 Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada. MX2014015557A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662576P 2012-06-21 2012-06-21
PCT/US2013/046230 WO2013192131A1 (en) 2012-06-21 2013-06-18 Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function

Publications (1)

Publication Number Publication Date
MX2014015557A true MX2014015557A (es) 2015-02-24

Family

ID=48626643

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015557A MX2014015557A (es) 2012-06-21 2013-06-18 Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.

Country Status (12)

Country Link
US (1) US20140051834A1 (es)
EP (1) EP2863954A1 (es)
JP (1) JP2015531748A (es)
KR (1) KR20150023826A (es)
CN (1) CN104582736A (es)
AR (1) AR091476A1 (es)
CA (1) CA2877363A1 (es)
HK (1) HK1209034A1 (es)
MX (1) MX2014015557A (es)
RU (1) RU2015101699A (es)
TW (1) TW201402611A (es)
WO (1) WO2013192131A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
NZ744257A (en) 2011-06-28 2022-10-28 Inhibrx Inc Serpin fusion polypeptides and methods of use thereof
WO2015035419A1 (en) * 2013-09-09 2015-03-12 Hoffmann-La Roche Inc. Dosages of gip/glp-1 co-agonist peptides for human administration
TR201902516T4 (tr) 2013-11-06 2019-03-21 Zealand Pharma As Glukagon-glp-1-gıp üçlü agonist bileşikleri.
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
EP3082847A1 (en) 2013-12-20 2016-10-26 Indiana University Research and Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
EP4299595A3 (en) 2014-05-02 2024-03-13 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
BR112017008525A2 (pt) * 2014-10-27 2018-01-30 Inhibrx Lp proteína de fusão isolada, e, métodos para tratamento ou alívio de um sintoma de uma doença ou distúrbio, para tratamento ou alívio de uma inflamação ou um sintoma de uma doença ou distúrbio inflamatório e para redução do risco de infecção em um indivíduo.
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
WO2016131893A1 (en) * 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
CN108699125B (zh) * 2015-12-31 2022-10-28 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂
EA201891990A1 (ru) * 2016-03-04 2019-04-30 Шайр Хьюман Дженетик Терапиз, Инк. Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
KR102635635B1 (ko) 2016-05-23 2024-02-14 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법
TW201829463A (zh) * 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
CN117886928A (zh) 2017-01-06 2024-04-16 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
CN107188953B (zh) * 2017-07-11 2020-04-28 中国农业科学院北京畜牧兽医研究所 胰高血糖素样肽-1类似物及其用途
KR102668688B1 (ko) 2018-07-23 2024-05-24 삼성디스플레이 주식회사 유기 발광 소자
CN110964116A (zh) * 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
CN111217915B (zh) * 2019-01-08 2021-05-14 东莞太力生物工程有限公司 GLP-1类似物Fc融合多肽及其应用
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
WO2020172072A1 (en) * 2019-02-21 2020-08-27 The General Hospital Corporation Glycoengineering immunoglobulin e
KR20210059153A (ko) 2019-11-14 2021-05-25 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
CN113150172B (zh) * 2021-04-28 2023-09-22 中国药科大学 Glp-1r/gipr双靶点激动剂融合蛋白及其制备方法与应用
IL309067A (en) * 2021-06-09 2024-02-01 Scripps Research Inst Long-range dual GIP/GLP-1 peptide conjugates and methods of use
CN115521368A (zh) * 2021-06-25 2022-12-27 江苏鸿永医药技术有限公司 毒蜥外泌肽-4衍生物
WO2023030444A1 (zh) * 2021-09-02 2023-03-09 广东东阳光药业有限公司 Glp-1/gip双靶多肽、融合蛋白及其应用
WO2023109928A1 (zh) * 2021-12-16 2023-06-22 上海宝济药业有限公司 抗免疫球蛋白降解酶酶切的Fc变体

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DE60032331T2 (de) 1999-01-14 2007-06-21 Amylin Pharmaceuticals, Inc., San Diego Exendine zur glucagon suppression
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) * 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
EA003922B1 (ru) 1999-05-17 2003-10-30 Конджачем, Инк. Продолжительно действующие инсулинотропные пептиды
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
AU2003248370A1 (en) 2002-02-27 2003-09-09 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
AU2003239478A1 (en) 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
EP2345671B8 (en) 2002-09-27 2023-01-11 Xencor, Inc. Optimized fc variants and methods for their generation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2831379T3 (es) 2003-10-09 2021-06-08 Ambrx Inc Derivados poliméricos para la modificación selectiva de proteínas
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
KR20070039593A (ko) * 2004-07-21 2007-04-12 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
ZA200700359B (en) * 2004-07-21 2008-12-31 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1817340B1 (en) 2004-11-12 2012-05-16 Xencor, Inc. Fc variants with altered binding to fcrn
US20060275282A1 (en) 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
US20090181037A1 (en) * 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
KR101666229B1 (ko) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
PE20100056A1 (es) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8551946B2 (en) * 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
WO2011109784A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Formulation of insulinotropic peptide conjugates

Also Published As

Publication number Publication date
EP2863954A1 (en) 2015-04-29
TW201402611A (zh) 2014-01-16
JP2015531748A (ja) 2015-11-05
KR20150023826A (ko) 2015-03-05
AR091476A1 (es) 2015-02-04
US20140051834A1 (en) 2014-02-20
CA2877363A1 (en) 2013-12-27
RU2015101699A (ru) 2016-08-10
WO2013192131A1 (en) 2013-12-27
CN104582736A (zh) 2015-04-29
HK1209034A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
MX2014015557A (es) Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
NZ600709A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
CL2013002474A1 (es) Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
SG10201805411YA (en) Chimeric antigen receptors
BR112014019901A2 (pt) proteínas de fator viii recombinante
IN2014MN01642A (es)
NZ611108A (en) Methods of treating fgf21-associated disorders
JP2014530253A5 (es)
WO2014150600A3 (en) Modified toxins
PL2919801T3 (pl) Stabilna kompozycja farmaceutyczna białka fuzyjnego TNFR:FC etanerceptu
MY160995A (en) Polypeptides with permease activity
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
GEP201706773B (en) Cx3cr1-binding polypeptides
EA033007B1 (ru) ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ
UA115436C2 (uk) Протираковий злитий протеїн
MX339203B (es) Proteina de fusion anticancer.
IL232867B (en) Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses
MX2014004953A (es) Ligadores basados en tirosina para la conexion desprendible de peptidos.
HK1221163A1 (zh) 融合多肽的替代配方
EA201591609A1 (ru) Варианты альфа-амилазы
PH12015501796B1 (en) IL-1á INHIBITOR COMPOSITION AND USE THEREOF
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
MX343589B (es) Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.
SG10201803999UA (en) Recombinant factor viii formulations